Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease.
about
Crohn's disease: an immune deficiency stateIntestinal permeability regulation by tight junction: implication on inflammatory bowel diseasesRole of Rho kinase signal pathway in inflammatory bowel diseaseThe significance of interferon-gamma-triggered internalization of tight-junction proteins in inflammatory bowel diseaseTranscript levels of different cytokines and chemokines correlate with clinical and endoscopic activity in ulcerative colitisProbiotic Lactobacillus spp. diminish Helicobacter hepaticus-induced inflammatory bowel disease in interleukin-10-deficient mice.Mechanism of IFN-gamma-induced endocytosis of tight junction proteins: myosin II-dependent vacuolarization of the apical plasma membraneInflammatory markers in population studies of aging.Crohn's disease, fatigue, and infliximab: is there a role for cytokines in the pathogenesis of fatigue?Preventative effects of a probiotic, Lactobacillus salivarius ssp. salivarius, in the TNBS model of rat colitis.Initiation of an inflammatory response in resident intestinal lamina propria cells -use of a human organ culture model.Stepwise regulation of TH1 responses in autoimmunity: IL-12-related cytokines and their receptors.Inflammatory bowel disease and the apical junctional complex.Colorectal carcinogenesis: Review of human and experimental animal studies.Th17 cells: a new therapeutic target in inflammatory dermatoses.Identification of novel bone-specific molecular targets of binge alcohol and ibandronate by transcriptome analysis.Hyperactivated B cells in human inflammatory bowel disease.Importance of disrupted intestinal barrier in inflammatory bowel diseases.Bacterial induction of proinflammatory cytokines in inflammatory bowel disease.The IL-23/IL-17 pathway in inflammatory bowel disease.Proteomics and metabolomics in inflammatory bowel disease.Mucosal healing in the era of biologic agents in treatment of inflammatory bowel disease.Intestinal barrier dysfunction: implications for chronic inflammatory conditions of the bowel.Inflammation and the Intestinal Barrier: Leukocyte-Epithelial Cell Interactions, Cell Junction Remodeling, and Mucosal Repair.Estrogen receptor-β signaling modulates epithelial barrier function.Expression of catalytic proteasome subunits in the gut of patients with Crohn's disease.Crohn's Disease and Ulcerative Colitis Show Unique Cytokine Profiles.Campylobacter and IFNgamma interact to cause a rapid loss of epithelial barrier integrity.Improvement of real-time polymerase chain reaction for quantifying TNF-alpha mRNA expression in inflamed colorectal mucosa: an approach to optimize procedures for clinical use.Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms.Does nicotine influence cytokine profile and subsequent cell cycling/apoptotic responses in inflammatory bowel disease?cDNA array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced colitis: homeostatic role of VIP.TNF promoter polymorphisms and modulation of growth retardation and disease severity in pediatric Crohn's disease.Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis.Moxibustion treatment restoring the intestinal epithelium barrier in rats with Crohn's disease by down-regulating tumor necrosis factor alpha, tumor necrosis factor receptor 1, and tumor necrosis factor receptor 2.Par-3 modulates intestinal epithelial barrier function through regulating intracellular trafficking of occludin and myosin light chain phosphorylation.Predictive value of mucosal TNF-alpha transcripts in steroid-refractory Crohn's disease patients receiving intensive immunosuppressive therapy.Familial aggregation and linkage analysis of autoantibody traits in pedigrees multiplex for systemic lupus erythematosusShort-and Long-Term Clinical Outcomes of Infliximab in Fulminant Ulcerative ColitisTherapeutic effectiveness of orally administered transgenic low-alkaloid tobacco expressing human interleukin-10 in a mouse model of colitis
P2860
Q22252579-EBC87937-664F-430E-91EC-6CF0429BFE1CQ26859272-045249BD-E152-4115-8B5C-62B6E9587323Q27006502-FE2CE755-FA16-4AB4-988C-7401EE86589FQ28289667-A4A4EC3D-3DF1-46DE-A4EE-55533C2D40C5Q33407000-2552BEDC-E7C7-460C-95B1-C87FBF6F838AQ33795727-792F5D9C-7F76-403A-A6B4-F316D86486B7Q34049874-018F2BFD-D75D-4E60-B72E-0F7477F0A46CQ34995451-7C76EA84-D40B-4A49-853C-30F4391EFB99Q35055957-5EF2C08B-6DC9-4FE6-BB6D-F74DCF7E472CQ35059717-87E2EA7B-8E6E-411F-8EC1-43A96AC8CAE6Q35171067-15D68040-E325-4ABC-9920-9478F1AA2514Q36207257-DBCF989E-A7C2-491D-BBBC-9E2B139BADB1Q36631468-6D4EF8A2-7F2C-4CE1-93E5-69F724AE00F1Q37183760-4016CF54-3255-451A-881D-53180CD6EF9FQ37216488-9A7D4BA3-576A-4C11-8AD7-C0556BE230B6Q37309830-48EFC744-256F-4B4F-BE87-11D888975EC1Q37486515-FCFA5619-865C-43D6-8C7B-03CA553C02FDQ37781315-0EB83808-B8DE-4A1B-B636-A24C0FB795F3Q37789694-5D602AF3-D6FB-4ED2-83C3-1CC9C5E07548Q37989164-D1E7F08E-E79F-4ED4-8592-FE145BA9B3FBQ38089179-925A746B-4441-4A33-8FA4-D17817F6F483Q38293774-3B502178-5567-475B-959A-3DF4D46C9D10Q38810502-45226489-D359-4FC7-B55E-C658FD4BE406Q38902578-ABC28204-96D7-4083-8132-3ED46F4A5ECBQ39605059-9C5B0ACB-9F9C-4EAE-B41A-FDF266765469Q41810371-B03C7BBB-41CD-41E6-93D0-71D3D5D0D844Q42255132-3CBC2AEC-94E1-4513-A877-847724C95E44Q42521994-A612A3BA-115E-47AE-B264-24E4BFA6F818Q44551224-DF3F9986-CB2F-4840-B870-2AA087C8CB89Q45285895-51E2404F-C74E-4384-844E-5FD15EE2581EQ46489592-AB317CC1-836E-44AC-AA02-DC9C0D3D5438Q46562251-DFCE3C5E-8B09-4821-B18D-7642D6ADE8C9Q46572217-306D1448-E839-463A-99F1-6360EC73B37FQ51763526-B5731AA8-98F0-4DE0-8C3E-40249C535F34Q52608505-A4A510BC-52A1-405A-8EA4-DDBE352F384FQ52955402-291A7BF8-13CF-40CB-A825-52C721D75859Q54563954-6B7FABBE-970F-4185-945B-5AC2BB5C7B0AQ57329898-AF64F8D5-8F5D-456E-A649-9D43DE48A223Q58694439-B43ACDD3-7518-4623-99F1-4873289372E6Q58917333-8CDDC814-F76E-4F8E-94A0-5522F43B50A8
P2860
Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease.
@en
Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease.
@nl
type
label
Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease.
@en
Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease.
@nl
prefLabel
Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease.
@en
Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease.
@nl
P2093
P1476
Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn's disease.
@en
P2093
Andreas Stallmach
Bianca Ludwig
Carsten Schmidt
Ina Mueller-Molaian
Stefan C Meuer
Thomas Giese
P2888
P304
P356
10.1007/S00384-003-0554-4
P577
2003-11-07T00:00:00Z